12月4日夜间,礼来放出“重磅炸弹”,称在一项头对头的三期临床研究中,其GIP/GLP-1双受体激动剂替尔泊肽的减重效果大幅超越诺和诺德的司美格鲁肽。这一消息推动礼来当天股价收盘大涨超过2%,市值逼近7900亿美元。 GLP-1药物在过去一年里成为多家巨头药企争相布局的热门赛道。巴克莱银行预计,到2030年,全球减重药物市场规模有望增至1500亿美元。 两家巨头减重药在中国迈入商业化 今年7月,...
Source Link12月4日夜间,礼来放出“重磅炸弹”,称在一项头对头的三期临床研究中,其GIP/GLP-1双受体激动剂替尔泊肽的减重效果大幅超越诺和诺德的司美格鲁肽。这一消息推动礼来当天股价收盘大涨超过2%,市值逼近7900亿美元。 GLP-1药物在过去一年里成为多家巨头药企争相布局的热门赛道。巴克莱银行预计,到2030年,全球减重药物市场规模有望增至1500亿美元。 两家巨头减重药在中国迈入商业化 今年7月,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.